Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes?
- PMID: 30517896
- DOI: 10.1016/j.cmet.2018.11.010
Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes?
Abstract
Heart failure and renal disease remain significant complications in people with type 2 diabetes (T2D). Recent outcome studies with sodium-glucose cotransporter-2 (SGLT2) inhibitors have provided increasing insights, with the latest reporting trial DECLARE-TIMI 58 (Wiviott et al., 2018), pointing toward a role for these agents in the primary prevention of cardio-renal complications in T2D.
Copyright © 2018 Elsevier Inc. All rights reserved.
Comment on
-
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415602 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
